Publications
- Randomized trial of adjuvant equitoxic dose-escalated anthracycline (A)-containing regimen of doxorubicin, cyclophosphamide (AC) versus cyclophosphamide, methotrexate, 5-FU (CMF) for stage 1-2 breast cancer (BrCa): Can equitoxicity compensate for agent selection?Publication without faculty affiliation
- Randomized trial of adjuvant equitoxic dose-escalated anthracycline (A)-containing regimen of doxorubicin, cyclophosphamide (AC) versus cyclophosphamide, methotrexate, 5-FU (CMF) for stage 1-2 breast cancer (BrCa): Can equitoxicity compensate for agPublication without faculty affiliation
- New treatment options for HER2-dependent metastatic breast cancer2011 | First Faculty of Medicine
- Breast cancer2011 | First Faculty of Medicine
- Hepatocellular carcinoma2010 | First Faculty of Medicine
- Standards of medical practice and quality in health care - Malignant tumors of the ovary2009 | First Faculty of Medicine
- The integrated care for the younger age group of women with breast cancer2008 | First Faculty of Medicine
- Influence of chemotherapy to hormonal levels in postmenopausal breast cancer patients2008 | First Faculty of Medicine
- HER-2 tissue expression correlated with serum levels in breast cancer patients2007 | First Faculty of Medicine
- cancer, anus2007 | First Faculty of Medicine
Loading network view...